Myostatin or activin antagonists for the treatment of sarcopenia

The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of o...

Full description

Saved in:
Bibliographic Details
Main Authors KLICKSTEIN LLOYD B, PAPANICOLAOU DIMITRIS, TRIFILIEFF ESTELLE, ROOKS DANIEL, ROUBENOFF RONENN, GLASS DAVID, KORTEBEIN PATRICK
Format Patent
LanguageChinese
English
Published 01.08.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age- related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function. 本发明涉及肌肉减少症或激活素拮抗剂，剂量方案及其药物组合物，用于治疗肌肉减少症，特别是年龄相关的肌肉减少症。具体地，发现肌肉抑制素或激活素拮抗剂拜马单抗在治疗患有肌肉减少症的老年人中关于增加其骨骼肌力量和功能而言有益。
Bibliography:Application Number: CN201580066991